Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 9, 2010, Pages 2050-2052

  Pinnetti, Carmela ^a   Baroncelli, Silvia ^b   Villani, Paola ^c   Fantoni, Massimo ^a   Tozzi, Valerio ^d   de Luca, Andrea ^a,e   Cauda, Roberto ^a   Anzidei, Gianfranco ^d   Cusato, Maria ^c   Regazzi, Mario ^c   Floridia, Marco ^b   Tamburrini, Enrica ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^e UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Drug plasma levels; HAART; Mother to child transmission

Indexed keywords

ATAZANAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; GLYCOPROTEIN P; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ABSENCE OF SIDE EFFECTS; ACIDITY; ADD ON THERAPY; CESAREAN SECTION; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; FETUS BLOOD; FETUS OUTCOME; GENE MUTATION; GESTATIONAL AGE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LETTER; LOW DRUG DOSE; MATERNAL BLOOD; MIXED INFECTION; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT MONITORING; PERINATAL INFECTION; PREGNANCY; PREGNANCY OUTCOME; VIREMIA; VIRUS LOAD;

EID: 77955641520     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq264     Document Type: Letter

References (7)

1. Public Health Service Task Force. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States - May 24, 2010. http://AIDSinfo.nih.gov (3 June 2010, date last accessed).
2. Grinsztejn B, Nguyen BY, Katlama C et al., for the Protocol 005 Team. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369: 1261-9.
3. Poirier JM, Robidou P, Jaillon P. Quantification of the HIV-integrase inhibitor raltegravir (MK-0518) in human plasma by high performance liquid chromatography with fluorescence detection. J Chromatography 2008; 867: 277-81.
4. Papendorp SG, van den Berk GE. Preoperative use of raltegravir- containing regimen as induction therapy: very rapid decline of HIV-1 viral load. AIDS 2009; 23: 739.
5. Sun M, Kingdom J, Baczyk D et al. Expression of the multidrug resistance P-glycoprotein (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta 2005; 27: 602-9.
6. Kassahun K, McIntosh I, Cui D et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007; 35: 1657-63.
7. Pinnetti C, Tamburrini E, Ragazzoni E et al. Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1. Antivir Ther 2010; 15: 127-9.